Alexander Jordan, MD

Perez K, Dias Costa A, Jordan A, Karasic T, Elganainy D, Kim S, Yuan C, Gui D, Tan R, Hong S, Wang X, Cristea S, Coleman E, Truitt M, Oh T, Zheng H, Furniss C, Brais L, Bird A, Remland J, Gocheva V, Thalappillil J, Anderson M, Cleary J, Enzinger A, Giannakis M, Ng K, Rubinson D, Schlechter B, Surana R, Singh H, Abrams T, Teitelbaum U, Izgur N, Allen E, Winter P, Raghavan S, Yeh J, Von Hoff D, Liddle C, Downes M, Evans R, O’Dwyer P, Aguirre A, Nowak J, Wolpin B. Gemcitabine and nab-paclitaxel with or without the VDR agonist paricalcitol for metastatic pancreatic cancer: a randomized, multiarm, run-in phase trial. Nature Cancer 2026, 7: 928-943. PMID: 42185478, PMCID: PMC13462977, DOI: 10.1038/s43018-026-01165-8.

Jun H, Tanaka Y, Johri S, Camp S, Bao E, Carvalho F, Gui D, Jordan A, Labaki C, Martin S, Nagy M, O'Meara T, Pappa T, Pimenta E, Saad E, Yang D, Gillani R, Tewari A, Reardon B, Van Allen E. A context-augmented large language model for accurate precision oncology medicine recommendations. Cancer Cell 2026, 44: 676-685.e4. PMID: 41544626, PMCID: PMC12811686, DOI: 10.1016/j.ccell.2025.12.017.

Singh H, Xiu J, Kapner K, Yuan C, Narayan R, Oberley M, Farrell A, Surana R, Huffman B, Perez K, Cleary J, Jordan A, Costa A, Williams H, Raghavan S, Weinberg B, Pishvaian M, Shroff R, Goel S, Dougan S, Nowak J, Spetzler D, Sledge G, Wolpin B, Aguirre A. Clinical and genomic features of classical and basal transcriptional subtypes in pancreatic cancer. Clinical Cancer Research 2024, 30: 4932-4942. PMID: 39283131, PMCID: PMC12267046, DOI: 10.1158/1078-0432.ccr-24-1164.

Dilly J, Hoffman M, Abbassi L, Li Z, Paradiso F, Parent B, Hennessey C, Jordan A, Morgado M, Dasgupta S, Uribe G, Yang A, Kapner K, Hambitzer F, Qiang L, Feng H, Geisberg J, Wang J, Evans K, Lyu H, Schalck A, Feng N, Lopez A, Bristow C, Kim M, Rajapakshe K, Bahrambeigi V, Roth J, Garg K, Guerrero P, Stanger B, Cristea S, Lowe S, Baslan T, Van Allen E, Mancias J, Chan E, Anderson A, Katlinskaya Y, Shalek A, Hong D, Pant S, Hallin J, Anderes K, Olson P, Heffernan T, Chugh S, Christensen J, Maitra A, Wolpin B, Raghavan S, Nowak J, Winter P, Dougan S, Aguirre A. Mechanisms of resistance to oncogenic KRAS inhibition in pancreatic cancer. Cancer Discovery 2024, 14: 2135-2161. PMID: 38975874, PMCID: PMC11528210, DOI: 10.1158/2159-8290.cd-24-0177.

Huffman B, Ellis H, Jordan A, Freed-Pastor W, Perez K, Rubinson D, Sethi N, Singh H, Surana R, Wolpin B, Aguirre A, Cleary J. Emerging Role of Targeted Therapy in Metastatic Pancreatic Adenocarcinoma. Cancers 2022, 14: 6223. PMID: 36551707, PMCID: PMC9776746, DOI: 10.3390/cancers14246223.

Fu C, Stoeckle J, Masri L, Pandey A, Cao M, Littman D, Rybstein M, Saith S, Yarta K, Rohatgi A, Makarov D, Sherman S, Morrissey C, Jordan A, Razzo B, Theprungsirikul P, Tsai J, Becker D. COVID‐19 outcomes in hospitalized patients with active cancer: Experiences from a major New York City health care system. Cancer 2021, 127: 3466-3475. PMID: 34096048, PMCID: PMC8239692, DOI: 10.1002/cncr.33657.

Ko A, Jordan A, Tooker E, Lacey S, Chang R, Li Y, Venook A, Tempero M, Damon L, Fong L, O'Hara M, Levine B, Melenhorst J, Plesa G, June C, Beatty G. Dual Targeting of Mesothelin and CD19 with Chimeric Antigen Receptor-Modified T Cells in Patients with Metastatic Pancreatic Cancer. Molecular Therapy 2020, 28: 2367-2378. PMID: 32730744, PMCID: PMC7647666, DOI: 10.1016/j.ymthe.2020.07.017.

Jordan A, Wu J. Immunotherapy in hepatocellular carcinoma: Combination strategies. World Journal Of Meta-Analysis 2020, 8: 190-209. DOI: 10.13105/wjma.v8.i3.190.

Salhi A, Jordan A, Bochaca I, Izsak A, Darvishian F, Houvras Y, Giles K, Osman I. Oxidative Phosphorylation Promotes Primary Melanoma Invasion. American Journal Of Pathology 2020, 190: 1108-1117. PMID: 32142731, PMCID: PMC7237828, DOI: 10.1016/j.ajpath.2020.01.012.

Xu J, Sai H, Li Y, Jordan A, McGettigan S, Chen J, Bedoya F, Fraietta J, Gladney W, Melenhorst J, Beatty G. Peripheral Blood T-Cell Fitness Is Diminished in Patients With Pancreatic Carcinoma but Can Be Improved With Homeostatic Cytokines. Cellular And Molecular Gastroenterology And Hepatology 2019, 8: 656-658.e6. PMID: 31398492, PMCID: PMC6889367, DOI: 10.1016/j.jcmgh.2019.07.008.

Grabiner B, Nardi V, Birsoy K, Possemato R, Shen K, Sinha S, Jordan A, Beck A, Sabatini D. A Diverse Array of Cancer-Associated MTOR Mutations Are Hyperactivating and Can Predict Rapamycin Sensitivity. Cancer Discovery 2014, 4: 554-563. PMID: 24631838, PMCID: PMC4012430, DOI: 10.1158/2159-8290.cd-13-0929.